Zobrazeno 1 - 10
of 348
pro vyhledávání: '"Merrill J Egorin"'
Autor:
Dae-Hee Lee, Ying Zhang, Amin B Kassam, Myung-Jin Park, Paul Gardner, Daniel Prevedello, Stephanie Henry, Craig Horbinski, Jan H Beumer, Hussein Tawbi, Brian J Williams, Mark E Shaffrey, Merrill J Egorin, Roger Abounader, Deric M Park
Publikováno v:
PLoS ONE, Vol 10, Iss 8, p e0134426 (2015)
The majority of chordomas show activation of the platelet-derived growth factor receptor (PDGFR). Based on in vitro intertumoral variation in response to recombinant PDGF protein and PDGFR inhibition, and variable tumor response to imatinib, we hypot
Externí odkaz:
https://doaj.org/article/b9e40afa3cfc436788788ef2f5fd5a4d
Autor:
Gary K. Schwartz, David Kelsen, Merrill J. Egorin, Nian Wu, Katia Manova-Todorova, Karen Brown, Robert Lefkowitz, Robert Maki, Ki Chung, Eileen O'Reilly, Caroll Tipian, Janet Mui, Richard Carvajal, Rachel Sikorski, Tahir Sheikh, Manish Shah, Mithat Gonen, David S. Klimstra, Archie N. Tse
Supplementary Data from A Phase 1 Dose-Escalation Study of Irinotecan in Combination with 17-Allylamino-17-Demethoxygeldanamycin in Patients with Solid Tumors
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4fd85d8ed7d6a9cc4d82a437c698b902
https://doi.org/10.1158/1078-0432.22439293.v1
https://doi.org/10.1158/1078-0432.22439293.v1
Autor:
Lillian L. Siu, Merrill J. Egorin, Julianne L. Holleran, Igor Espinoza-Delgado, Wen-jiang Zhang, Lisa Wang, Shauna McGill, Lee-Anne Stayner, Anne Laughlin, Sheila Webster, Patricia Moretto, Amit M. Oza, Holger W. Hirte, Eric X. Chen, Sebastien J. Hotte, Anastasios Stathis
Supplementary Figure S1.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8c0422847df9e3a8453edb9d56aa4e04
https://doi.org/10.1158/1078-0432.22442208.v1
https://doi.org/10.1158/1078-0432.22442208.v1
Autor:
Lillian L. Siu, Merrill J. Egorin, Julianne L. Holleran, Igor Espinoza-Delgado, Wen-jiang Zhang, Lisa Wang, Shauna McGill, Lee-Anne Stayner, Anne Laughlin, Sheila Webster, Patricia Moretto, Amit M. Oza, Holger W. Hirte, Eric X. Chen, Sebastien J. Hotte, Anastasios Stathis
Purpose: This phase I study evaluated the safety, tolerability, pharmacokinetics, and preliminary efficacy of the combination of decitabine with vorinostat.Patients and Methods: Patients with advanced solid tumors or non-Hodgkin's lymphomas were elig
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::00707092063e5fcdd3f45bde6e041bf6
https://doi.org/10.1158/1078-0432.c.6519009
https://doi.org/10.1158/1078-0432.c.6519009
Autor:
Gary K. Schwartz, David Kelsen, Merrill J. Egorin, Nian Wu, Katia Manova-Todorova, Karen Brown, Robert Lefkowitz, Robert Maki, Ki Chung, Eileen O'Reilly, Caroll Tipian, Janet Mui, Richard Carvajal, Rachel Sikorski, Tahir Sheikh, Manish Shah, Mithat Gonen, David S. Klimstra, Archie N. Tse
Purpose: Both heat shock protein 90 (Hsp90) and checkpoint kinase 1 (Chk1) have emerged as novel therapeutic targets. We conducted a phase I study of irinotecan and the Hsp90 inhibitor 17AAG, which can also down-regulate Chk1, in patients with solid
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1e8870e1664fdf7960b4412ae60017f0
https://doi.org/10.1158/1078-0432.c.6516787.v1
https://doi.org/10.1158/1078-0432.c.6516787.v1
Autor:
Kenneth P. Nephew, Tim H.M. Huang, Curtis Balch, Kate M. Brannon, Adam Golas, Annie P. Moseman, Merrill J. Egorin, Eleanor G. Zuhowski, Milos Novotny, Jason A. Starkey, John S. Montgomery, Phillip H. Abbosh
Supplementary Figures S5-S7 from Dominant-Negative Histone H3 Lysine 27 Mutant Derepresses Silenced Tumor Suppressor Genes and Reverses the Drug-Resistant Phenotype in Cancer Cells
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::109a003215eaab96f0b7326863d750a1
https://doi.org/10.1158/0008-5472.22364520
https://doi.org/10.1158/0008-5472.22364520
Autor:
Kenneth P. Nephew, Tim H.M. Huang, Curtis Balch, Kate M. Brannon, Adam Golas, Annie P. Moseman, Merrill J. Egorin, Eleanor G. Zuhowski, Milos Novotny, Jason A. Starkey, John S. Montgomery, Phillip H. Abbosh
Histone modifications and DNA methylation are epigenetic phenomena that play a critical role in many neoplastic processes, including silencing of tumor suppressor genes. One such histone modification, particularly at H3 and H4, is methylation at spec
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3c124f266d5e0e4f9d6ca451d00242a7
https://doi.org/10.1158/0008-5472.c.6494223
https://doi.org/10.1158/0008-5472.c.6494223
Autor:
Merrill J. Egorin, Sonja Anderson, Kurt A. Jaeckle, Jann N. Sarkaria, Patrick J. Flynn, Paul D. Brown, Caterina Giannini, Erin Twohy, Jan C. Buckner, Jesse G. Dixon, Robert B. Jenkins, John Schwerkoske, Evanthia Galanis
Publikováno v:
J Neurooncol
Purpose: To evaluate the pharmacokinetics and efficacy of imatinib in patients with recurrent oligodendroglial tumors. Methods: Patients with progressive WHO grade II-III recurrent tumors after prior RT and chemotherapy were eligible. A phase I dose-
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3027c2aa34d5ab673720ad402d92d765
http://hdl.handle.net/11585/723449
http://hdl.handle.net/11585/723449
Autor:
Kimberly P. Kicielinski, Dana M. Clausen, Julie L. Eiseman, Jan H. Beumer, Robert A. Parise, Pamela A. Hershberger, Merrill J. Egorin
Publikováno v:
Cancer Chemotherapy and Pharmacology. 76:537-546
Benzaldehyde dimethane sulfonate (BEN, DMS612, NSC281612) is a bifunctional alkylating agent currently in clinical trials. We previously characterized the degradation products of BEN in plasma and blood. The conversion of BEN to its carboxylic acid a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cd651d6c86daf7ca42871d39cc85deb1
https://doi.org/10.1007/s00280-015-2828-2
https://doi.org/10.1007/s00280-015-2828-2
Autor:
Lee-Anne Stayner, Eric Chen, Lillian L. Siu, Tracy S. Wong, Jonathan How, Leber Brian, Patricia Haines, Mark D. Minden, Igor Espinoza-Delgado, Sheila Webster, Joseph Brandwein, Shauna McGill, Aaron D. Schimmer, Tammy Degelder, Merrill J. Egorin, Lisa Wang, Andre C. Schuh, Vikas Gupta, Richard Piekarz, Karen W.L. Yee, Julianne L. Holleran
Publikováno v:
Leukemia & Lymphoma. 56:2793-2802
This phase I trial evaluated two schedules of escalating vorinostat in combination with decitabine every 28 days: (i) sequential or (ii) concurrent. There were three dose-limiting toxicities: grade 3 fatigue and generalized muscle weakness on the seq
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fc31321541e960021e61cd873740c3d7
https://doi.org/10.3109/10428194.2015.1018248
https://doi.org/10.3109/10428194.2015.1018248